Gemcitabine (G) plus cisplatin (C) is a highly active regimen in first-line treatment of metastatic breast cancer (MBC): Results of a multicenter phase II trial

被引：0
|
作者：
Fuentes, H
Calderillo, G
Alexander, F
Ramirez, M
Avila, E
Perez, L
Aguirre, C
机构：
[1] Inst Nacl Cancerol, SSA, Mexico City, DF, Mexico
[2] Hosp Gen Occidente Seguro Social, SSA, Oncol Serv, Guadalajara, Jalisco, Mexico
[3] IMSS, Unidad Morelos 1, Cuernavaca, Morelos, Mexico
[4] Ctr Med Potosi, Oncol & Radiotherapy Serv, San Luis Potosi, Mexico
[5] Clin ISSSTE, Oncol Serv, Ensenada, Baja California, Mexico
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
10.1016/S0959-8049(02)80216-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
130
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [31] Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer
    Hoelzer, K. L.
    Brufsky, A.
    Hainsworth, J.
    Beck, J. T.
    Whorf, R.
    Keaton, M.
    Kroener, J.
    Krill-Jackson, E.
    Hu, S.
    Bromund, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract
    Karachaliou, Niki
    Polyzos, Aris
    Kentepozidis, Nikolaos
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Milaki, Georgia
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    ONCOLOGY, 2010, 78 (5-6) : 356 - 360
  • [33] Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: Results of a phase II study
    Klaassen, U
    Wilke, H
    Muller, C
    Borquez, D
    Harstrick, A
    Seeber, S
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 58 - 60
  • [34] Final results of gemcitabine (G) and epirubicin (E) phase II trial in metastatic breast cancer (MBC) patients (pts).
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Serin, D
    Petit, T
    Espie, M
    Kayitalire, L
    Robert, C
    Pouillart, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S90 - S90
  • [35] Navelbine (N) capecitabine (C) combination (Navcap); the new first line chemotherapy regimen for metastatic breast cancer (MBC): results of phase II trial.
    Ghosn, M
    Kattan, J
    Farhat, F
    Gasmi, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S133 - S133
  • [36] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
  • [37] Phase II study of gemcitabine plus cisplatin in metastatic breast cancer
    Fuentes, Homero
    Calderillo, German
    Alexander, Francisco
    Ramirez, Marcelino
    Avila, Enrique
    Perez, Leonel
    Aguirre, Guillermo
    Onate-Ocana, Luis F.
    Gallardo, Dolores
    Otero, Jorge
    ANTI-CANCER DRUGS, 2006, 17 (05) : 565 - 570
  • [38] A prospective, multicenter, phase II trial of albumin-paclitaxel plus cisplatin versus gemcitabine plus cisplatin in first-line treatment of advanced biliary tract tumors.
    Yang, Xiao
    Zhuang, Liang
    Dai, Yuhong
    Qiu, Hong
    Yuan, Xianglin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC) patients.: Final results from a phase II GOTI trial.
    Pérez-Manga, G
    López-Criado, P
    Méndez, M
    Quiben, R
    Palomero, I
    Sancho, JF
    Belón, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S205 - S206
  • [40] Multicenter Phase II Trial of First-line Docetaxel/Gemcitabine in Advanced Breast Cancer Pretreated with Adjuvant Anthracyclines
    Vici, Patrizia
    Giotta, Francesco
    Di Lauro, Luigi
    Brandi, Mario
    Gebbia, Vittorio
    Foggi, Paolo
    Lorusso, Vito
    Vitucci, Carlo
    Sergi, Domenico
    Fattoruso, Silvia Ileana
    Giannarelli, Diana
    Viola, Giuditta
    Corsetti, Serena
    Colucci, Giuseppe
    Lopez, Massimo
    ANTICANCER RESEARCH, 2009, 29 (05) : 1841 - 1845
12345